About This Blog

Welcome to the WordPress blog for pharmaceutical industry executive Dr. Lindsay Rosenwald. On this blog, readers can access a broad range of articles relevant to his past and present philanthropic and professional endeavors, as well as his involvement with academic institutions. Visitors to this page will also find information and news on medical advances, the U.S. Food and Drug Administration (FDA), the pharmaceutical and biotechnology fields, and a variety of other related topics. As a graduate of the Temple University School of Medicine and a venture capitalist, Dr. Rosenwald possesses a wealth of knowledge in both the investment and medical industries, making him uniquely qualified to share that knowledge with readers. Accordingly, the intersection of finance and health care will be a focus of this blog, with particular emphasis on investment news in the biotechnology and pharmaceutical sectors.

Specializing in investment opportunities in these sectors, Dr. Lindsay Rosenwald has co-founded a number of companies involved in the development of more than 100 potentially life-saving treatments. His achievements include co-founding and funding Cougar Biotechnology, which went on to develop a pharmaceutical treatment for prostate cancer that was approved for Phase II clinical trials by the FDA. After the trials were completed, Cougar Biotechnology was acquired by Johnson & Johnson for nearly $1 billion, an unprecedented sum for a biotechnology firm in the early development stage. The drug has since achieved full FDA approval and is now sold under the name Zytiga.

Dr. Rosenwald also played a key role in the development of arsenic trioxide, which is used to treat acute promyelocytic leukemia. In addition, he has contributed to the development of pharmaceutical treatments for several other diseases, such as schizophrenia, rheumatoid arthritis, and fibromyalgia. Companies he has been involved in include Keryx Biopharmaceuticals, where he served on the Board of Directors; Interneuron Pharmaceuticals, Inc.; and Neose Technologies, Inc.

Dr. Rosenwald began his career in medicine as a physician in private practice. During the 1980s, he combined his interests in finance and medicine as a physician advisor on Wall Street before gaining further experience in asset management as managing director of a private investment firm that focused on opportunities in the health care industry. In 1991, he founded his first biotechnology asset management firm, launching a career in the field that has spanned more than two decades.

Today, Dr. Lindsay Rosenwald serves as partner and co-founder of an investment partnership that targets promising companies in the health care industry. In addition, he contributes to his alma mater, the Temple University School of Medicine, as a member of its Board of Visitors. Also a graduate of Pennsylvania State University, where he earned his bachelor of science in finance, Dr. Rosenwald remains involved with the university as an honorary member of the Board of Visitors for the Smeal College of Business. As a philanthropist, Dr. Rosenwald is the founder of the Rosenwald Foundation, through which he has donated generously to numerous charitable organizations.


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: